A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
- Carcinoma, Non-Small-Cell Lung
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Enrolment target
- 130
- Started
- 6 December 2024
- Main results due
- 31 December 2028
- Study sites
- 44
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening * Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization * Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification * Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 Exclusion Criteria: * Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression * Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV * Another concurrent or prior primary malignancy within the last 36 months at informed consent * Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab * History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Study sites(44)
Moores Cancer Center at UC San Diego Health
La Jolla, California, United States
Recruiting
University of Connecticut Health Center
Farmington, Connecticut, United States
Completed
Yale University
New Haven, Connecticut, United States
Recruiting
University of Miami
Miami, Florida, United States
Recruiting
Orlando Health Cancer Institute
Orlando, Florida, United States
Recruiting
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Recruiting
Washington University in St Louis
St Louis, Missouri, United States
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Recruiting
NYU Langone Health
New York, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Recruiting
FirstHealth of the Carolinas
Pinehurst, North Carolina, United States
Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Recruiting
Oregon Health And Science University
Portland, Oregon, United States
Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Recruiting
MD Anderson Cancer Center
Houston, Texas, United States
Recruiting
University of Vermont Medical Center
Burlington, Vermont, United States
Recruiting
Royal Brisbane and Women's Hospital
Herston, Australia
Recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia
Recruiting
Macquarie University
North Ryde, Australia
Recruiting
Royal Melbourne Hospital
Parkville, Australia
Recruiting
Fundacao Pio XII
Barretos, Brazil
Recruiting
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
São Paulo, Brazil
Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil
Recruiting
Dongguan People s Hospital
Dongguan, China
Recruiting
The First Affiliated Hospital Sun Yat sen University
Guangzhou, China
Recruiting
The Affiliated Cancer Hospital of Shandong First Medical University
Jinan, China
Recruiting
Hopital De La Cavale Blanche
Brest, France
Recruiting
Hopital Nord Marseille
Marseille, France
Recruiting
Hopital Tenon
Paris, France
Recruiting
Institut Curie
Paris, France
Recruiting
CHU Rouen Hopital Charles Nicolle
Rouen, France
Recruiting
Gustave Roussy
Villejuif, France
Recruiting
Prince of Wales Hospital
Shatin, Hong Kong
Recruiting
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Recruiting
Radboud Umcn
Nijmegen, Netherlands
Recruiting
Hosp. Univ. 12 de Octubre
Madrid, Spain
Recruiting
Clinica Univ. de Navarra
Pamplona, Spain
Recruiting
Hosp. Clinico Univ. de Santiago
Santiago de Compostela, Spain
Recruiting
Hosp. Univ. I Politecni La Fe
Valencia, Spain
Recruiting
Marmara University Pendik Training Hospital
Istanbul, Turkey (Türkiye)
Recruiting
Sakarya University Training and Research Hospital
Sakarya, Turkey (Türkiye)
Recruiting
University College London Hospitals
London, United Kingdom
Recruiting
Showing 44 of 44 sites. 43 of the 44 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06667908. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me